FATE

Fate Therapeutics, Inc.

3.76 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Fate Therapeutics, Inc. stock is up 9.62% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 72.73% of the previous 10 June’s closed higher than May. 100% of analysts rate it a buy.

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc. develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cells product candidates.